Dr. Brayer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
12902 Magnolia Drive
Tampa, FL 33612Phone+1 813-745-4167Fax+1 813-745-6817- Is this information wrong?
Education & Training
University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2011 - 2015- University of South Florida MorsaniResidency, Internal Medicine, 2009 - 2011
- University of South Florida College of MedicineClass of 2009
H. Lee Moffitt Cancer Center and Research InstitutePost-Doctoral Fellowship, Immunology, 2002 - 2005
La Jolla Institute for Allergy and ImmunologyPost-Doctoral Fellowship, Division of Immune Regulation, 2000 - 2002
Certifications & Licensure
FL State Medical License 2011 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2019 Jan 23
Roles: Contact
Publications & Presentations
PubMed
- 2 citationsCardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.Dae Hyun Lee, Abhishek Kumar, Turab Mohammed, Lauren C Peres, Melissa Alsina, Christina Bachmeier, Brandon J Blue, Jason Brayer, Sanjay Chandrasekhar, Ariel Grajales C...> ;Blood Advances. 2023 Aug 22
- 15 citationsCYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): hae...David A Sallman, Tessa Kerre, Violaine Havelange, Xavier Poiré, Philippe Lewalle, Eunice S Wang, Jason B Brayer, Marco L Davila, Ine Moors, Jean-Pascal Machiels, Ahmad...> ;The Lancet. Haematology. 2023 Mar 1
- 23 citationsEarly cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.Jennifer M Logue, Lauren C Peres, Hamza Hashmi, Christelle M Colin-Leitzinger, Alexandria M Shrewsbury, Hitomi Hosoya, Rebecca M Gonzalez, Christina Copponex, Krista H...> ;Blood Advances. 2022 Dec 27
- Join now to see all
Abstracts/Posters
- Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis...Jason B. Brayer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple MyelomaJason B. Brayer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple MyelomaJason B. Brayer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Professional Memberships
- Member
- Member
- Member
- Society for Immunotherapy of CancerMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
